Drug Action II E3 Objectives PDF

DRUG ACTION II E3 OBJECTIVES SKELETALMUSCLE RELAXANTS \-- Bennett 1\. Identify the MOA and ADR of a drug that works as depolarizing neuromuscular agent 2\. Identify the MOA, names of the drugs that work as non-depolarizing neuromuscular agents. Which one is better in patients with ARS 3\. Identi...

DRUG ACTION II E3 OBJECTIVES SKELETALMUSCLE RELAXANTS \-- Bennett 1\. Identify the MOA and ADR of a drug that works as depolarizing neuromuscular agent 2\. Identify the MOA, names of the drugs that work as non-depolarizing neuromuscular agents. Which one is better in patients with ARS 3\. Identify MOA and ADRs of centrally acting spasmolytic drugs: baclofen, cyclobenzaprine, diazepam, carisoprodol, and tizanidine. 4\. Identify important counseling point when using spasmolytic drugs 5\. Identify the names of other drugs that can be useful as spasmolytics 6\. Identify specific characteristics of Cisatracurium CNS STIMULANTS -- Bennett 1\. Identify sign/problems of ADHD and how psychostimulants can improve ADHD Problems 2\. Compare and contrast psychostimulants and psychomimetics using known drugs 3\. Identify MOA, ADRs, BBW (if any) and component of Adderall XR®, Concerta®, Vyvanse®, Ritalin LA®, and Dexedrine capsule ® 4\. Identify ADRs, contraindication and management of overdose of psychostimulants 5\. Identify MOA, ADRs, BBW, and DDI of atomoxetine 6\. Identify MOA, ADR and use of alpha 2 agonists 7\. Identify MOA, characteristics, ADR of modafinil and other drug for treatment of Narcolepsy CNS STIMULANTS AND MUSCLE RELAXANTS -- Daniels Describe the MOA of stimulants and muscle relaxants discussed Discuss the SAR of key drug classes where presented Identify clinically significant physiochemical and pharmacokinetic properties of stimulants and muscle relaxants discussed Discuss, with chemical structures, the clinically significant metabolism of stimulants and muscle relaxants discussed and how that affects their activity ENDOCRINE -- HYPOTHALAMIC/PITUITARY AGENTS 1\. Identify drugs useful to treat acromegaly, their MOA and ADRs 2\. Identify relationship between DA, GH, prolactin and acromegaly 3\. Identify MOA, ADRs, DDI of recombinant human growth factor 4\. State MOA, drug classes, ADRs, and DDI of drugs to treat Cushing syndrome 5\. Identify MOA, use and ADRs of spironolactone 6\. Identify drugs useful to treat Addison and how to take the drugs 7\. Identify MOA, use of oxytocin and Atosiban 8\. Identify drugs that can induce hyper-PRL 9\. Identify ADRs of glucocorticosteroids IBD AGENTS -- BENNETT 1\. Differentiate UC and CD, area being affected, different in the immunologic properties being activated, and primary symptoms of the disease 2\. Identify names and classes of drugs useful to treat IBD 3\. Identify MOA, ADRs, active compound, supplementation needed for sulfasalazine 4\. Identify MOA and ADRs of glucocorticoids 5\. Identify MOA, ADRs, DDI effect on slow and fast metabolizers , and metabolites being made from thiopurines 6\. Identify MOA, ADRs, use, and antidote of methotrexate at low and high dose 7\. Define MOA, identify drug names, ADRs of anti-TNF α agents. Identify drug with more potency and reason of potency 8\. Identify MOA, ADRs, drug names of : integrin receptor antagonist, Janus kinase inhibitor, cyclosporine, inhibitor of IL12/23, SP-1 modulator ANTIARRYTHMICS -- KUHL AND DANIELS Describe the MOA of the classes of anti-arrhythmic agents Identify clinically significant physiochemical and pharmacokinetic properties of anti-arrhythmic agents Discuss, the clinically significant metabolism of anti-arrhythmic agents and how that affects their activity and drug interactions Explain how differences in metabolism can result in differences in adverse effects Identify chemically derived clinically significant adverse effects and their causes Explain the influence of acidosis & alkalosis on Class 1 agents Explain chemical basis for short duration of action of esmolol